| Document |
Document Title |
|
WO/2013/144228A1 |
The present invention relates to pesticidal methods for the use and application of substituted heterocyclic compounds of formula (I) and the stereoisomers, salts, tautomers and N-oxides thereof and to compositions comprising the same. Th...
|
|
WO/2013/137832A1 |
The invention relates to myostatin inhibitors, and in particular, to myostatin inhibitors comprising small molecules, and pharmaceutical compositions comprising the myostatin inhibitors. The invention also relates to methods for treating...
|
|
WO/2013/134080A2 |
The subject invention describes a method of use of Ropinirole TM to alleviate and control menopausal symptoms in women, and in particular, hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for...
|
|
WO/2013/134061A1 |
The present invention provides novel phenicol derivatives of formula I, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.
|
|
WO/2013/124413A1 |
The present invention relates to new thiadiazolidmediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is invol...
|
|
WO/2013/122028A1 |
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...
|
|
WO/2013/123047A1 |
Small organic molecule semi-conducting chromophores containing a halogen-substituted core structure are disclosed. Such compounds can be used in organic heterojunction devices, such as organic small molecule solar cells and transistors.
|
|
WO/2013/123349A1 |
Methods of producing a sulfilimine compound, such as N-cyano-S-methyl-S-[1-(6-trifluoromethyl-3-pyridinyl)ethyl]s
ulfilimine or other substituted sulfilimine compound. The method includes combining a sulfide compound, cyanamide, a hypoch...
|
|
WO/2013/118854A1 |
Provided is a drug for the treatment and/or prevention of pain or a drug for the treatment and/or prevention of sodium channel-mediated diseases. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: Ar...
|
|
WO/2013/108026A1 |
According to the invention there is provided a compound of formula I, wherein, R1 to R4 have meanings given in the description, which compounds are useful in the treatment of diabetes.
|
|
WO/2013/107283A1 |
Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1 and X2 is as defined in the description. These compounds are protein kinases inhibitors, especiall...
|
|
WO/2013/097773A1 |
The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.
|
|
WO/2013/090454A2 |
The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of ...
|
|
WO/2013/086229A1 |
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. (The Formula I should be inserted here.) The compounds are ...
|
|
WO/2013/078123A1 |
The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases us...
|
|
WO/2013/063458A2 |
This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.
|
|
WO/2013/059582A2 |
The disclosure relates to small molecules and methods, compositions, and kits comprising these small molecules. In still another embodiment, the disclosure relates to small molecules that inhibit HDAC activity. In yet another embodiment,...
|
|
WO/2013/043491A1 |
Corrosion of metallic tubulars in an oil, gas or geothermal well may be inhibited by introducing into the well a dithiazine derivative. The dithiazine may be isolated from a whole spent fluid (WSF) formed by reaction of hydrogen sulfide ...
|
|
WO/2013/029294A1 |
Disclosed in the present invention is a 2-sulfhydryl-4,5-dimethyl-1,3,4-thiadiazole (A), a lithium salt (B), a diploid (C) and a synthesis process thereof. The micromolecule thiadiazole of the structure and derivates thereof can be used ...
|
|
WO/2013/031694A1 |
A compound represented by general formula or a salt thereof is useful as an antifungal agent. (In the formula, R1 and R2 may be the same or different and each represents a halogen atom, a cyano group, a nitro group, an optionally substit...
|
|
WO/2013/024168A1 |
The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxym...
|
|
WO/2013/022047A1 |
The present invention provides a compound which has an inhibitory activity on lysine-specific demethylase 1 and is useful as a medicinal agent such as a prophylactic or therapeutic agent for cancer and central nervous system diseases. Th...
|
|
WO/2013/018735A1 |
The purpose of the present invention is to provide a novel compound which has an anti-fungal activity on pathogenic fungi including fungi belonging to the genus Candida, the genus Aspergillus and the genus Trichophyton and is useful as a...
|
|
WO/2013/019731A2 |
A compound of formula: wherein R1, L A, R, and n are defined herein, is useful for treating various disorders, including diarrhea.
|
|
WO/2013/014204A2 |
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...
|
|
WO/2013/012665A2 |
Embodiment of the present disclosure can include a compound, a structure bonded to the compound, and the like. In an embodiment, the compound can be a linker between an agent and a structure, where the agent can be a dye or a pigment and...
|
|
WO/2013/004642A1 |
The present invention relates to a compound of formula (IA) The present invention also relates to the use of the compound of formula IA for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or agg...
|
|
WO/2013/005157A1 |
Provided herein is novel compound of the general formula (I), its tautomeric forms, its stereoisomers, its analogs, its prodrugs, its isotopes, its N- oxides, its metabolites, its pharmaceutically acceptable salts, its polymorphs, its so...
|
|
WO/2012/176856A2 |
To provide a novel pesticide. The present invention provides a compound represented by the formula (I) or its salt, and a pesticide containing it as an active ingredient: (I) wherein each of R1 and R2 is a hydrogen atom, a halogen atom, ...
|
|
WO/2012/175654A1 |
Tetraline sulfonamides derivatives highly specific towards CA IX and/or CA XII human carbonic anhydrase for targeting solid tumors.
|
|
WO/2012/170536A1 |
The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a t...
|
|
WO/2012/162323A1 |
A method for treating hypertension in a subject in need thereof (e.g., wherein said treatment does not result in an increase in serum uric acid levels, abnormally elevated serum uric acid levels, hyperuricemia, serum uric acid levels of ...
|
|
WO/2012/147516A1 |
[Problem] To provide a GPR40 activating agent having as an active ingredient a novel compound having a GPR40 agonist action, or a salt thereof, a solvate of the compound or salt, or the like; in particular, an insulin secretagogue or an ...
|
|
WO/2012/149335A2 |
The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states ...
|
|
WO/2012/147764A1 |
Provided is a novel compound having NPY Y5 receptor antagonistic activity. It was discovered that a compound represented by (1) (where R1 is an optionally substituted alkyl and the like; p, q, and r are each independently 0 or 1; ring A ...
|
|
WO/2012/149189A2 |
This disclosure relates to a photovoltaic cell that includes a first electrode, a second electrode, and a photoactive layer disposed between the first and second electrodes. The photoactive layer includes a photoactive polymer containing...
|
|
WO/2012/142671A1 |
The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of th...
|
|
WO/2012/140251A1 |
The invention relates to a rubber composition for the production of tyres, containing one or more diene elastomers, one or more reinforcing fillers and a vulcanisation system. The composition is characterised in that the vulcanisation sy...
|
|
WO/2012/138734A1 |
In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula : (I) and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said ...
|
|
WO/2012/126570A1 |
The invention relates to combinations having at least one bicyclic or tricyclic ring system, which is connected by acetylene ethylene or difluoroethylene bridges, to the application thereof in high frequency components, to liquid crystal...
|
|
WO/2012/121168A1 |
The purpose of the present invention is to provide: a novel compound having an excellent CK2-inhibiting activity and high safety; and use applications of the compound. Provided are: a CK2 inhibitor comprising, as an active ingredient, a ...
|
|
WO/2012/082893A2 |
High performance organic photovoltaic cells based on donor acceptor polymers in the active layer. A composition comprising: at least one copolymer comprising at least one first donor moiety and at least one first acceptor moiety in the c...
|
|
WO/2012/079164A1 |
The present invention is directed to activators of cylindrical proteases ("ACPs"), particularly ClpP, and the role thereof in the diagnosis and treatment of bacterial infections. A number of ACPs were identified that activate caseinolyti...
|
|
WO/2012/077478A1 |
Aspects of the present invention can provide a novel phenanthrothiadiazole compound with the lowest excited triplet level T1 that is high, the phenanthrothiadiazole compound being capable of forming a stable amorphous film. Furthermore, ...
|
|
WO/2012/070066A1 |
The present invention relates to a process for the preparation of substantially pure Taurolidine.
|
|
WO/2012/062210A1 |
The compound of formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complex thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The...
|
|
WO/2012/050484A2 |
The invention relates to organic chemistry, more specifically to novel biologically active compounds in the form of 5-amino-1,2,4-thiadiazole derivatives of general formula (I), where X may be ONO2 or NHR3; R1, R2, R3 may be the same or ...
|
|
WO/2012/046869A1 |
[Problem] To provide a GPR40 activator, particularly an insulin secretion stimulator or a prophylactic and/or therapeutic agent for diabetes, obesity or the like, which contains a novel compound having a GPR40 agonistic activity, a salt ...
|
|
WO/2012/012307A9 |
Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which ...
|
|
WO/2012/025638A1 |
The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors their production and use, especially for the treatment and/or prophylaxis of hormone-related diseases.
|
